What Midatech Pharma PLC does

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), doing business as Biodexa and referred to in some source records as Midatech Pharma PLC, is a clinical-stage biopharmaceutical company headquartered in the United Kingdom and developing a pipeline of treatments for diseases with high unmet medical need. The company's portfolio is centered on three core programs: eRapa, MTX240, and Tolimidone. eRapa is a proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor, that uses nanotechnology and pH sensitive polymers to improve bioavailability and produce more consistent pharmacokinetics than existing formulations. It is being readied for a Phase 3 registration study — branded the Serenta Trial — in familial adenomatous polyposis (FAP), a rare condition for which the only current effective intervention is bowel resection and where patients otherwise progress to colorectal cancer. MTX240 is a next-generation molecular glue (OPB-171775) licensed exclusively from Otsuka for all territories outside Japan, targeting TKI-resistant gastrointestinal stromal tumor (GIST). Tolimidone is an orally delivered, selective inhibitor of lyn kinase that has demonstrated glycemic control via insulin sensitization in animal models of type 1 diabetes.

Biodexa's underlying technology platform combines proprietary drug formulation science (nanotechnology and pH-sensitive polymer engineering applied to a known active pharmaceutical ingredient), an in-licensed targeted protein degradation asset, and a small-molecule kinase inhibitor approach. Its competitive positioning rests on the established safety profile of rapamycin (approved in the US for renal transplant rejection), the territorial exclusivity of the Otsuka license, and the orphan/rare-disease nature of the lead indications, where existing therapeutic options are limited.

The business is pre-revenue and pre-commercial: the company generates no product sales, has not disclosed pricing, and does not yet employ traditional go-to-market or distribution channels. Its activity is concentrated on clinical development, regulatory progression, and capital-markets engagement via its NASDAQ listing, with a Serenta Trial patient-recruitment website and standard investor-relations infrastructure as its principal outward-facing assets.

Name

Midatech Pharma PLC

Legal name

Biodexa Pharmaceuticals PLC

Website

https://midatechpharma.com

Company type

Public

Operating status

Operating

Short description

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing eRapa (oral rapamycin) for familial adenomatous polyposis, MTX240 (a molecular glue) for TKI-resistant GIST, and Tolimidone (a lyn kinase inhibitor) for type 1 diabetes, targeting rare and serious diseases with unmet medical need.

Ownership category

akta.pro rank

Product category

Clinical-Stage Rare Disease Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Clinical-stage biopharmaceutical
• Rare disease therapeutics
• Oral rapamycin formulation
• Molecular glue degraders
• MTOR inhibitor drugs

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Distribution channels2 records

Marketing channels5 records

Core offering

Biodexa Pharmaceuticals PLC (formerly Midatech Pharma PLC) is a clinical-stage biopharmaceutical company developing a pipeline of therapeutics for rare and serious diseases with high unmet medical need. Its lead asset eRapa is a proprietary oral tablet formulation of rapamycin using nanotechnology and pH-sensitive polymers, being readied for a Phase 3 study in familial adenomatous polyposis (FAP). The pipeline also includes MTX240, a next-generation molecular glue licensed from Otsuka for TKI-resistant GIST, and Tolimidone, an oral lyn kinase inhibitor with potential first-in-class application in type 1 diabetes.

Product overview

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company operates three core programs: eRapa (oral rapamycin formulation for FAP, in phase 3 readiness), MTX240 (molecular glue for TKI-resistant GIST), and Tolimidone (lyn kinase inhibitor for type 1 diabetes). The company is also working on treatments for primary and metastatic cancers of the brain.

Differentiator

Problem solved

Functional benefit

Products and services

• eRapa Proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor, designed to improve bioavailability and achieve more consistent pharmacokinetics than existing formulations. Lead indication is familial adenomatous polyposis (FAP), a rare condition where the only successful treatment is bowel resection and patients otherwise progress to colorectal cancer. Rapamycin is already approved in the US for organ rejection in renal transplantation.
• MTX240 (OPB-171775) Next-generation molecular glue (OPB-171775) targeting TKI-resistant gastrointestinal stromal tumor (GIST), a rare sarcoma with approximately 4,000-6,000 new US cases annually. Induces selective protein degradation to overcome standard-of-care limitations such as imatinib resistance. Licensed exclusively from Otsuka in all territories outside Japan.
• Tolimidone Orally delivered, potent and selective inhibitor of lyn kinase, a member of the Src family of protein tyrosine kinases mainly expressed in hematopoietic cells, neural tissues, liver, and adipose tissue. Demonstrates glycemic control via insulin sensitization in animal models of diabetes and has potential to become a first-in-class blood glucose modulating agent for type 1 diabetes.
• Serenta Trial Phase 3 clinical study evaluating eRapa versus placebo for the ability to improve clinical outcomes in patients with familial adenomatous polyposis (FAP). The study is open for enrollment in the US and is conducted through clinical trial sites.

Quantifiable outcome

• eRapa is being readied for phase 3 registration study in familial adenomatous polyposis (FAP)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• vTv Therapeutics: Clinical-stage biopharma with a Type 1 diabetes program, directly comparable to Biodexa's Tolimidone. Both pursue novel, non-insulin mechanisms for T1D glycemic control from a small-cap clinical base.
• Deciphera Pharmaceuticals: Pioneered approved GIST therapy (Qinlock/ripretinib) for TKI-resistant disease. Operates in the same rare oncology niche as Biodexa's MTX240 and shares the same clinical-stage-to-commercial rare disease playbook.
• Crinetics Pharmaceuticals: Clinical-stage biopharma developing treatments for endocrine and metabolic rare diseases. Comparable specialty-pharma positioning, therapeutic area overlap (endocrine/metabolic), and similar small-cap clinical-stage operating model.
• Cogent Biosciences: Clinical-stage biopharma developing treatments for TKI-resistant GIST, directly overlapping with Biodexa's MTX240 program. Same rare sarcoma indication and similar resistance-focused mechanism positioning make it the closest direct comparable.
• Provention Bio: Was focused on Type 1 diabetes therapies (teplizumab) before acquisition by Sanofi. Closely comparable to Biodexa in targeting T1D as a clinical-stage specialty biopharma.

Broad incumbents

• Revolution Medicines: Larger clinical-to-commercial oncology company developing targeted therapies including protein degraders and RAS inhibitors. Operates in the same novel-mechanism oncology space as Biodexa but at a more advanced and broader scale.
• Blueprint Medicines: Established precision oncology biopharma with approved kinase inhibitors and broader pipeline. Comparable in therapeutic area (targeted oncology) but at a more advanced commercial and scale stage than Biodexa.

Emerging players

• Aprea Therapeutics: Clinical-stage company developing molecular glue / targeted protein degradation therapies in oncology. Mechanism overlap with Biodexa's MTX240 makes it a comparable emerging player in the same modality class.
• Molecular Partners: Clinical-stage biopharma developing novel biologics including targeted protein degradation approaches. Comparable as a small-cap clinical-stage innovator pursuing novel therapeutic modalities in oncology and serious diseases.
• Lexicon Pharmaceuticals: Small-cap biopharma with diabetes and metabolism programs historically. Shares Biodexa's small-cap, clinical-stage profile and metabolic disease focus, though its development stage differs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/@biodexa_pharma
• LinkedInlinkedin.com/company/midatech-pharma-plc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Midatech Pharma PLC